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Background-—Low high-density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on
statin treatment with low-density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet
activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as
determinants of atherothrombosis.
Methods and Results-—Urinary 8-iso-PGF2a and 11-dehydro-TXB2, in vivo markers of oxidative stress and platelet activation,
respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/dL, and in 47
CHD patients with HDL >35 mg/dL. The 2 eicosanoids were also measured before and after an intensive exercise program in
sedentary people (n=18) and before and after fenoﬁbrate treatment in otherwise healthy subjects with low HDL (n=10). Patients
with HDL ≤35 mg/dL showed signiﬁcantly higher urinary 8-iso-PGF2a (median [25th to 75th percentiles]: 289 [189 to 380] versus
216 [171 to 321] pg/mg creatinine, P=0.019) and 11-dehydro-TXB2 (563 [421 to 767] versus 372 [249 to 465] pg/mg creatinine,
P=0.0001) than patients with higher HDL. A direct correlation was found between urinary 8-iso-PGF2a and 11-dehydro-TXB2 in the
entire group of patients (q=0.77, P<0.0001). HDL levels were inversely related to both 8-iso-PGF2a (q=0.32, P=0.001) and
11-dehydro-TXB2 (q=0.52, P<0.0001). On multiple regression, only 8-iso-PGF2a (b=0.68, P<0.0001) and HDL level (b=0.29,
P<0.0001) were associated with urinary 11-dehydro-TXB2 excretion, independent of sex, age, smoking, hypertension, diabetes,
previous myocardial infarction, total cholesterol, LDL, and triglycerides. Both intensive exercise and fenoﬁbrate treatment
signiﬁcantly reduced the 2 eicosanoids in healthy subjects, in parallel with an HDL increase.
Conclusions-—A low HDL phenotype, both in CHD patients and in healthy subjects, is associated with increased lipid peroxidation
and platelet activation. These data provide novel insight into the mechanisms linking low HDL with increased CV risk. ( J Am Heart
Assoc. 2013;2:e000063 doi: 10.1161/JAHA.113.000063)
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H igh-density lipoprotein (HDL) cholesterol is a majorindependent risk factor for coronary heart disease
(CHD).1
A low level of HDL cholesterol (HDL-C) is a powerful
predictor of increased cardiovascular (CV) risk,2 and it
remains a signiﬁcant risk factor in people whose LDL
cholesterol (LDL-C) is reduced to very low levels.3 Indeed,
HDL-C levels are predictive of major CV events in patients
treated with statins, both when HDL-C is considered as a
continuous variable and when subjects are stratiﬁed accord-
ing to quintiles of HDL-C level. Even among subjects with
LDL-C levels <70 mg/dL, those in the highest quintile of
HDL-C level are at less risk for major CV events than those in
the lowest quintile.3 Furthermore, the ratio of LDL to HDL
cholesterol is also highly predictive of the risk of major CV
events.
In patients with established CV disease, residual CV risk
persists despite the achievement of target LDL-C levels with
statin therapy. Among patients with atherosclerotic CV
disease and LDL-C levels <70 mg/dL, there is no incremen-
tal clinical beneﬁt from the addition of niacin to statin
therapy during a 36-month follow-up period, despite signif-
icant improvements in HDL–C and triglyceride levels.4
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Similarly, therapy with the cholesterol ester transfer protein
(CEPT) inhibitor torcetrapib, despite a 72% increase in HDL-C
levels, resulted in an increased risk of CV mortality and
morbidity.5 However, the clinical failure of torcetrapib
intervention trials has been related to “off-target” effects
on neurohumoral regulation of blood pressure and increased
risk of arrhythmias. In addition, CEPT inhibition generates
large amounts of large HDL particles that are not optimally
functional.6
Interventions aimed at increasing HDL-C levels prevent the
progression of CHD.7 In fact, niacin therapy, by increasing
HDL levels, causes a signiﬁcant regression of carotid intima–
media thickness when combined with a statin, as compared
with ezetimibe.8 Interestingly, the incidence of major CV
events is lower in the niacin group than in the ezetimibe
group.8 Intensive statin regimen, either with atorvastatin or
rosuvastatin, results in very low levels of LDL-C as well as a
slight increase in HDL. The 2 regimens are similar in their
ability to limit progression or induce regression of coronary
disease evaluated by intravascular ultrasonography.9
In addition to its cholesterol-transporting properties, HDL
favorably regulates endothelial cell phenotype, promoting the
production of nitric oxide (NO) by upregulating endothelial NO
synthase expression. Moreover, HDL’s antithrombotic prop-
erties may be related to their abilities to attenuate the
expression of tissue factor and selectins and to downregulate
thrombin generation via the protein C pathway, thus directly
and indirectly blunting platelet activation.10
HDL exhibits antioxidant activity by inhibition of LDL
oxidation with a subsequent reduction of cellular uptake by
the monocyte macrophage system.11 A normo-triglyceridemic,
low HDL-C phenotype is characterized by elevated oxidative
stress and HDL particles with attenuated antioxidant activ-
ity.12 Antioxidant activity of small dense HDL is deﬁcient in
type 2 diabetes, and it is linked to enhanced oxidative
stress.13 The increased generation of reactive oxygen species
may induce enhanced lipid peroxidation of cell-membrane
phospholipids or circulating LDL, leading to the increased
generation of F2-isoprostanes, a family of prostaglandin
isomers produced from arachidonic acid by a mechanism
catalyzed by free radicals.14,15 F2-isoprostanes can modulate
the activation of platelets induced by low levels of other
agonists.16 The consistent relationship between the rates of
formation of F2-isoprostanes and thromboxane (TX) in several
metabolic disorders16 suggests that TX-dependent platelet
activation may be mediated, at least in part, by enhanced lipid
peroxidation.17 This vicious cycle may be downregulated by a
successful weight-loss program in obesity18 or by tight
metabolic control obtained by insulin treatment in type 2
diabetes mellitus.19
We speculated that increased oxidative stress in CHD
patients with a low-HDL phenotype could induce enhanced
generation of 8-iso-prostaglandin (PG)F2a and other biologi-
cally active isoeicosanoids and that these compounds, in turn,
could contribute to platelet activation in this setting.17
Therefore, in the present study, we set out to investigate
whether 8-iso-PGF2a formation is increased in CHD patients
with lower HDL levels (≤35 mg/dL) when compared with CHD
patients with higher HDL levels (>35 mg/dL) and no signif-
icant differences in the other known CV risk factors and
whether it correlates with the rate of TXA2 biosynthesis.
Moreover, we examined the effects of 2 interventions aimed
at increasing HDL levels, that is, fenoﬁbrate treatment and 8
weeks of a standardized aerobic program, in otherwise
healthy subjects with a low-HDL phenotype by assessing
time-related changes in urinary 8-iso-PGF2a and in TX-
dependent platelet activation.
The results of the present study suggest that enhanced
peroxidation of arachidonic acid to form biologically active
isoprostanes may represent an important biochemical link
between the low-HDL phenotype and persistent platelet
activation in this setting.
Methods
Design of the Studies
The ﬁrst study was a cross-sectional comparison of urinary
F2-isoprostane 8-iso-PGF2a and 11-dehydro-TXB2 (a major
enzymatic metabolite of TXA2) of 65 normocholestoremic
CHD patients with HDL-C levels ≤35 mg/dL (52 men, aged 62
[54 to 70] years) with 47 normocholestoremic CHD patients
with HDL-C levels >35 mg/dL (30 men, aged 65 [57 to
68] years). CHD incidents (including angina pectoris, exercise
stress testing positive for ischemia, and acute myocardial
infarction in the previous 24 months) were recorded from the
outpatient database or from hospital discharge diagnoses. All
subjects were attending the Lipid Clinics of the University of
Palermo School of Medicine. CV risk factors such as smoking,
hypertension, and diabetes were equally represented in the
2 groups (Table 1).
None of the patients had taken any drugs known to affect
lipid metabolism or platelet function for ≥2 weeks before the
start of the study because they were unwilling to do so.
Patients with renal insufﬁciency or proteinuria (by serum
creatinine level and urinalysis), altered hepatic function (by
liver enzymes), or alcohol abuse were excluded.
All subjects were studied as outpatients after a 12-hour fast.
Blood samples were obtained for the following measurements:
total cholesterol, triglycerides, HDL cholesterol. Each patient
performed a 12-hour overnight urine collection immediately
before blood sampling. Urine samples were supplemented with
the antioxidant 4-hydroxy-tempo (1 mmol/L) and stored at
20°C until extraction.
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The study was approved by the local Ethics Committee,
and all patients gave their written informed consent to
participate in the study.
A second study was performed to investigate the effects of
regular high-amount, high-intensity aerobic exercise on in vivo
lipid peroxidation and platelet activation in 18 healthy
sedentary people with low HDL-C levels. We evaluated
whether changes in HDL-C levels, induced by the exercise
program, were related to changes in the 2 eicosanoids. Each
participant completed an 8-week standardized aerobic high-
amount, high-intensity training program. Urinary 8-iso-PGF2a
and 11-dehydro-TXB2 excretion rates had been measured
before and after this intervention.
After giving written informed consent, 18 subjects (13 men,
aged 50 [48 to 66] years) had been enrolled in the study.
Subjects were enrolled if they had a sedentary lifestyle
(regular aerobic exercise <3 times/weeks and <20 minutes/
session), had a sedentary occupation, and had a baseline HDL
cholesterol concentration <55 mg/dL (<1.4 mmol/L).
Exclusion criteria included obesity (body mass index [BMI]
≥30 kg/m2), diagnosis of diabetes mellitus, poorly controlled
hypertension or hypercholesterolemia, pregnancy, impaired
liver or renal function, previous vascular event (myocardial
infarction, stroke, transient ischemic attack), or other medical
conditions that would preclude vigorous exercise, and treat-
ment with nonsteroidal anti-inﬂammatory drugs (NSAIDs),
antioxidant supplements, anticoagulants, or antiplatelet drugs.
Each participant completed an 8-week standardized aero-
bic training program. The exercise training involved 2 sessions
per week of supervised exercise on a cycle ergometer
(Monark 915E, Vansbro, Sweden). The exercise prescription in
the exercise group was high-amount, high-intensity exercise
for 55 minutes per session, the caloric equivalent of jogging
20 miles (32.0 km) per week at 60% to 75% of peak oxygen
consumption.20 There was an initial period of 1 month during
which the amount and intensity of exercise were gradually
increased, followed by 8 weeks at the appropriate exercise
prescription. Participants started at 55% of their baseline VO2
max for 45 minutes per session and progressed in intensity or
duration every week according to a standardized protocol
until achieving the standards scheduled for the training
program (55 minutes at 75% of baseline VO2 max). All
exercise sessions were veriﬁed by direct supervision or by
heart rate monitors that provided recorded data (Polar
Electro). Daily energetic consumption was monitored by
metabolic armband (Sensewear Pro3).
A third study was performed to investigate the effects of
3-month administration of fenoﬁbrate (145 mg/day) to 10
subjects (7 men, aged 58 [55 to 60] years) with a low-HDL
phenotype and triglycerides >200 mg/dL, otherwise healthy,
previously unresponsive to an appropriate dietary regimen
(checked regularly by a qualiﬁed nutritionist). The 10 subjects
were allocated to continue the previous diet plus fenoﬁbrate for
3 months.
All patients had a positive familial history for CV events
younger than age 65. Exclusion criteria included obesity (BMI
≥30 kg/m2), diabetes mellitus, poorly controlled hypertension
or hypercholesterolemia, pregnancy, impaired liver or renal
function, previous vascular event (myocardial infarction,
stroke, transient ischemic attack), and treatment with NSAIDs,
antioxidant supplements, anticoagulants, or antiplatelet drugs.
This study was approved by the local Ethics Committee,
and all patients gave their written informed consent to
participate in the study.
Table 1. Clinical Characteristics of CHD Patients
Variables HDL-C ≤35 mg/dL (n=65) HDL-C >35 mg/dL (n=47) P Value*
Age, y 62 (54 to 70) 65 (57 to 68) 0.439
Male sex, n (%) 52 (80) 30 (64) 0.09
Total cholesterol, mg/dL 155 (133 to 180) 166 (152 to 182) 0.063
Triglycerides, mg/dL 84 (55 to 153) 85 (62 to 116) 0.874
HDL-C, mg/dL 28 (25 to 32) 43 (39 to 47) <0.001
LDL-C, mg/dL 110 (89 to 122) 99 (87 to 113) 0.153
Cigarette smoking, n (%) 21 (32) 13 (20) 0.749
Arterial hypertension, n (%) 36 (55) 28 (43) 0.804
Type 2 diabetes, n (%) 26 (40) 14 (22) 0.36
Previous MI, n (%) 24 (37) 16 (25) 0.90
Continuous variables are reported as median (25th to 75th percentiles). CHD indicates coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; MI, myocardial infarction.
*By Mann–Whitney, chi-square, or Fisher exact tests, as appropriate.
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Assays
All participants were instructed to perform an overnight urine
collection and underwent a fasting blood sample drawn the
following morning. Plasma, serum, and urine were stored in
aliquots at 20°C until used for the various analyses.
Urinary 8-iso-PGF2a and 11-dehydro-TXB2 excretion rates
were measured by previously described radioimmunoassay
methods.21,22 These methods have been validated by com-
parison with gas chromatography/mass spectrometry, as
detailed elsewhere.21,22
Total cholesterol, triglycerides, high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein cholesterol
(LDL-C) concentrations were measured as previously
described.23
Statistical Analysis
The Kolmogorov–Smirnov test was used to determine whether
each variable had a normal distribution. When necessary, log-
transformation was used to normalize the data, or appropriate
nonparametric tests were used. Comparisons of baseline data
between the groups were performed by chi-square statistics,
Fisher exact tests, or Mann–Whitney U tests.
The differences between baseline and posttreatment
values were analyzed with the Wilcoxon signed rank test.
The association of eicosanoid measurements with other
biochemical parameters was assessed by the Spearman rank
correlation test.
Stepwise multiple linear regression analysis was performed
to assess variables independently associated with urinary
11-dehydro-TXB2 excretion rates, with logarithmically trans-
formed data for this analysis and forward selection of
variables. Covariates included in the multiple regression
models were selected on the basis of their signiﬁcance in
univariate analysis and their clinical relevance to the outcome
of interest, as reported from other studies. They included sex,
age, smoking, hypertension, diabetes, previous myocardial
infarction, total cholesterol, LDL-C, HDL-C, triglycerides, and
urinary 8-iso-PGF2a.
All values are reported as median (interquartile range [IQR]).
P values <0.05 were regarded as statistically signiﬁcant. All
tests were 2-tailed, and analyses were performed using the
SPSS (version 16.0; APSS, Chicago, IL), statistical package.
Results
The baseline characteristics of the 112 CHD patients are
detailed in Table 1. The 2 groups of patients (CHD with HDL-C
levels ≤35 and >35 mg/dL) were comparable both for sex
distribution and for age. No statistically signiﬁcant differences
were found between the 2 groups of patients for CV risk
factors.
Urinary excretion rate of the F2-isoprostane 8-iso-PGF2a
was signiﬁcantly (P=0.019) higher in the CHD patients with
HDL ≤35 mg/dL than in the patients with higher HDL levels:
289 (189 to 380) versus 216 (171 to 321) pg/mg creatinine
(Figure 1A). Moreover, patients with HDL ≤35 mg/dL had a
signiﬁcantly (P=0.0001) higher excretion rate of 11-dehydro-
TXB2, an index of in vivo platelet activation, than did patients
with higher HDL levels: 563 (421 to 767) versus 372 (249 to
465) pg/mg creatinine (Figure 1B).
As depicted in Figure 2, a highly statistically signiﬁcant
direct correlation was found between the rates of excretion of
8-iso-PGF2a and 11-dehydro-TXB2 in both groups of patients
(q=0.77, P<0.0001), suggesting a potential link between lipid
peroxidation and platelet activation in this setting. In the
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Figure 1. Urinary levels of 8-iso-PGF2a (A) and 11-dehydro-TXB2 (B) in normocholesterolemic CHD patients, according to HDL cholesterol levels.
The horizontal dotted lines denote the median value for each study group. 8-iso-PGF2a indicates 8-iso-prostaglandin F2a; 11-dehydro-TXB2,
11-dehydrothromboxane B2; CHD, coronary heart disease; HDL, high-density lipoprotein.
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entire group of CHD patients, HDL level was inversely related
to both 8-iso-PGF2a (q=0.32, P=0.001) and 11-dehydro-
TXB2 (q=0.52, P<0.0001); see Figure 3.
On multiple regression analysis, only urinary 8-iso-PGF2a
(b=0.68, t=10.6, P<0.0001) and HDL level (b=0.29, t=4.56,
P<0.0001) were associated with urinary 11-dehydro-TXB2
levels, independently of sex, age, smoking, hypertension,
diabetes, previous myocardial infarction, total cholesterol,
LDL-C, and triglycerides.
Effects of the Exercise Program
We investigated the effects of an 8-week standardized high-
amount, high-intensity aerobic exercise on in vivo lipid
peroxidation and platelet activation in 18 healthy sedentary
people with low HDL cholesterol levels. Because weight loss
may signiﬁcantly affect in vivo lipid peroxidation and platelet
activation,18 subjects were given the recommendation of
maintaining body weight during the 2-month period, and thus
they had a small but not signiﬁcant weight gain.
Exercise training had no signiﬁcant effect on total choles-
terol or LDL-C concentrations. There was a statistically
signiﬁcant increase (P=0.041) of HDL-C levels, from 47.5
(42.5 to 49.0) to 52.5 (45.0 to 61.3) mg/dL, after the high-
amount, high-intensity training period. There was also a
signiﬁcant reduction in triglyceride concentration (from 119
[92 to 177] to 95 [77 to 118] mg/dL, P=0.025).
The 8-week exercise program was associated with a
signiﬁcant reduction in the urinary excretion rate of both
8-iso-PGF2a and 11-dehydro-TXB2 (by 25% [9.3% to 58%] and
29% [20% to 40%], respectively, versus baseline; P<0.0001;
Figure 4A and 4B).
Statistically signiﬁcant inverse correlations were found
between HDL-C and 11-dehydro-TXB2 levels (q=0.38,
P=0.023) over the 8-week training period by pooling the data
obtained before and after exercise (Figure 4C).
Effects of Fenoﬁbrate
We next examined the effects of 3 months of administration
of fenoﬁbrate (145 mg/day) on the urinary excretion of 8-iso-
PGF2a and 11-dehydro-TXB2 in subjects with a low-HDL
phenotype and triglycerides >200 mg/dL but otherwise
healthy to test the hypothesis of a cause–effect relationship
between a low-HDL phenotype and enhanced lipid peroxida-
tion and platelet activation in the setting of healthy people
with low HDL-C levels.
After fenoﬁbrate treatment, HDL-C levels were signiﬁcantly
increased, by 14% (5.0% to 25%; P=0.007), whereas triglyc-
eride levels were signiﬁcantly decreased, by 41% (38% to 46%;
P=0.005). Despite this, both urinary 8-iso-PGF2a and
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Figure 2. Correlation between urinary 8-iso-PGF2a and 11-dehydro-
TXB2 in CHD patients with HDL cholesterol ≤35 mg/dL (closed
circles) and with HDL >35 mg/dL (open circles). 8-iso-PGF2a
indicates 8-iso-prostaglandin F2a; 11-dehydro-TXB2, 11-dehydro-
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11-dehydro-TXB2 excretion rates were not signiﬁcantly
changed in the whole group. However, in the 5 subjects in
whom fenoﬁbrate induced an increase of HDL cholesterol
level above the median, we observed a signiﬁcant reduction in
urinary 8-iso-PGF2a and 11-dehydro-TXB2 excretion rates, by
39% (27% to 45%) and 70% (45% to 72%), respectively
(P=0.043) in comparison with no signiﬁcant modiﬁcations
obtained in the 5 subjects who had an increase of HDL
cholesterol below the median (Figure 5). Moreover, in the
former group of subjects, all individual values of urinary
8-iso-PGF2a and 11-dehydro-TXB2 levels fell within the range
of those of healthy subjects.18 Finally, the changes in
8-iso-PGF2a levels were also associated with the reduction
in urinary 11-dehydro-TXB2 levels because a statistically
signiﬁcant correlation was found between the rates of
excretion of these eicosanoids throughout the range of values
measured at baseline and after 3 months of administration of
145 mg of fenoﬁbrate (q=0.77, P=0.009).
Discussion
Low HDL-C is an independent CV risk factor, and the increase
of HDL-C of only 1 mg/dL leads to a risk reduction of 2% to
3%.1,2 Despite aggressive LDL-C lowering with statin therapy,
a residual risk of CV morbidity and mortality still occurs in a
signiﬁcant portion of subjects.3,4 There is compelling evidence
in animal models that increasing HDL levels is antiathero-
genic.1 Therefore, raising HDL-C was thought of as a strategy
for reducing the residual CV risk. However, a recent
systematic review and meta-regression analysis of random-
ized controlled trials24 has suggested that increasing the
amount of HDL-C does not reduce the risk of coronary heart
disease events and mortality.
HDLs have several protective properties that are indepen-
dent of their involvement in cholesterol metabolism. They
have antiatherogenic properties that reduce oxidation and
vascular inﬂammation and improve endothelial function, thus
promoting endothelial repair. Among antioxidant properties of
HDL, the transfer of oxidized lipids from LDL to HDL, including
oxidized phospholipids such as hydroperoxides and
F2-isoprostanes, facilitates subsequent degradation of these
products by HDL enzymes or by delivery to the liver for
degradation, thus preventing pathological activities of these
molecules. Normal functional HDL has high anti-oxidant
potential, but when these antioxidant functions are over-
whelmed by pathological processes, HDL is converted into a
dysfunctional particle characterized by decreased anti-inﬂam-
matory and antioxidant properties.25
In vitro studies show that HDL inhibits agonist-stimulated
platelet aggregation.26 This inhibitory effect is mediated by
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scavenger receptor type B1 and/or the apolipoprotein E
receptor apoER2/LRP8 and is linked to the induction of
intracellular signaling cascades encompassing stimulation
of protein kinase C, cytoplasmatic alkalization, and generation
of nitric oxide. Moreover, the infusion of Apo A-1 Milano (a
protective variant of the major protein constituent of HDL)
into rats inhibits platelet aggregation.10
However, no evidence has been provided for the associ-
ation between a low-HDL phenotype and in vivo platelet
activation as well as in vivo lipid peroxidation.
Biochemical evidence of increased platelet activation in
vivo was obtained through noninvasive measurements of TX
metabolite excretion22,27 that avoided artifactual platelet
activation during and after blood sampling. Although we did
not measure platelet aggregation in our study, it should be
emphasized that the ex vivo measurement of platelet
responses to various agonists represents an index of
functional capacity that by no means reﬂects the extent of
platelet activation in vivo.27 The excretion rate of the major
enzymatic metabolite of TXA2, 11-dehydro-TXB2, has been
validated as a reliable and noninvasive, integrated index of in
vivo platelet activation.17
Moreover, increased generation of reactive oxidant species
can induce enhanced lipid peroxidation of cell-membrane
phospholipids or circulating LDL, leading to increased gener-
ation of F2-isoprostanes, bioactive compounds produced from
arachidonic acid by a free radical–catalyzed mechanism of
lipid peroxidation.28 Activated platelets are also a source of
reactive oxidant species (by NADPH oxidase)29 and might
contribute to isoprostane generation by COX-dependent
mechanisms.30 It has been proposed that F2-isoprostanes
might transduce the effects of oxidant stress associate with
complex metabolic disorders into specialized forms of cellular
activation. In particular, 8-iso-PGF2a might be able to modify
platelet adhesive reactions and platelet activation in vitro by
low concentrations of agonists.16
In the present report, we performed a series of studies to
test the hypothesis that persistent in vivo platelet activation
maybe related, at least in part, to enhanced urinary excretion
of the F2-isoprostane 8-iso-PGF2a as a marker of in vivo lipid
peroxidation in the setting of a low-HDL phenotype.
In the ﬁrst study, we performed a cross-sectional evalu-
ation of the 2 eicosanoids in normocholesterolemic CHD
patients, and we found that the formation and urinary
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Figure 5. Urinary levels of 8-iso-PGF2a and 11-dehydro-TXB2 in 10 healthy individuals with low HDL cholesterol and hypertriglyceridemia before
and after a 3-month fenoﬁbrate (145 mg/day) treatment. A and B, Subjects who had an increase in HDL cholesterol above the median. C
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excretion of 8-iso-PGF2a was elevated in the vast majority of a
relatively large group of patients with HDL-C levels <35 mg/dL
in comparison with a group of CHD patients with higher
HDL-C levels, carefully characterized for other variables
potentially inﬂuencing lipid peroxidation (see Table 1).28
Moreover, we have identiﬁed a novel mechanism through
which low HDL-C levels may affect CV morbidity and mortality,
that is, TX-dependent platelet activation. In fact, low HDL-C
levels in CHD patients were associated with a signiﬁcantly
higher rate of TX metabolite excretion than measured in CHD
patients with higher HDL-C levels. The consistent linear
relationship between the excretion of rates of 8-iso-PGF2a and
11-dehydro-TXB2 demonstrated in our study conﬁrms and
extends previous ﬁndings in subjects with other CV risk
factors such diabetes mellitus or hypercholesterolemia.17
Further evidence for a cause-and-effect relationship
between low HDL-C level and persistent platelet activation
was obtained through 2 interventional studies: the ﬁrst in
sedentary people, the second in subjects with low HDL-C
levels but otherwise healthy.
When we performed a study with a high-intensity, high-
amount exercise program for 2 months for sedentary people,
we observed signiﬁcant decreases in both TX-dependent
platelet activation (11-dehydro-TXB2) and lipid peroxidation
(8-iso-PGF2a), with an inverse correlation between the TX
metabolite and HDL level. Our data are in accordance with a
recent study of adolescents with metabolic syndrome report-
ing that a physical activity program induced amelioration of
HDL levels as well as of markers of oxidative stress.31
In healthy subjects with low HDL-C and high triglycerides,
the reduction in both lipid peroxidation and TX-dependent
platelet activation was proportional to the effect of fenoﬁbrate
on HDL levels. In fact, HDL-C increase above the median led
to normalization of the 2 noninvasive indexes of platelet
activation and lipid peroxidation. This is consistent with the
ﬁnding that age-related changes in middle-aged nonobese
men show a simultaneous decrease in HDL-C levels as well as
plasma oxidative stress markers (8-iso-PGF2a and malondi-
aldehyde).32
The results of our study suggest that markers of lipid
peroxidation and TX-dependent platelet activation may be
useful synergistically with measurement of dysfunctional
HDLs to improve CV risk stratiﬁcation in patients with low
HDL-C.
Several limitations of the intervention studies should be
acknowledged. These include lack of randomization and small
sample size of the 2 interventional studies. Despite these
limitations, our ﬁndings may have important clinical implica-
tions for primary and secondary prevention in patients with a
low HDL phenotype, providing novel insight into the mecha-
nisms linking low HDL and occurrence of CV disease. In fact,
within the limits of our relatively small mechanistic studies with
biochemical end points, our results suggest that a substantial
reduction in TX-dependent platelet activation can be achieved
by a signiﬁcant increase in HDL levels obtained through
different tools (exercise and fenoﬁbrate). For subjects who fail
to achieve a substantial HDL-C increase, low-dose aspirin may
be considered as an option after evaluating the potential
beneﬁt and hemorrhagic risk of the individual patient.33
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